Covid-19 — Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
Citation(s)
Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial